Telix Pharmaceuticals (ASX:TLX) ROE % Adjusted to Book Value : 0.58% (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Telix Pharmaceuticals ROE % Adjusted to Book Value?

Telix Pharmaceuticals's ROE % for the quarter that ended in Dec. 2024 was 8.34%. Telix Pharmaceuticals's PB Ratio for the quarter that ended in Dec. 2024 was 14.49. Telix Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was 0.58%.

Telix Pharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for Telix Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals ROE % Adjusted to Book Value Chart

Telix Pharmaceuticals Annual Data

Trend

Sep99

Sep00

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-4.49

-0.20

-8.81

0.21

0.96

Telix Pharmaceuticals Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial										-2.49	-0.78	1.59	1.39	0.58

Competitive Comparison of Telix Pharmaceuticals's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Telix Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telix Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Telix Pharmaceuticals's ROE % Adjusted to Book Value falls into.

Telix Pharmaceuticals ROE % Adjusted to Book Value Calculation

Telix Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	13.92%	/	14.49
	=	0.96%

Telix Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	8.34%	/	14.49
	=	0.58%

Telix Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Telix Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (ASX:TLX) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

TLX:USA TLPPF:USA T3X:Germany

Address

55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051

Website

https://www.telixpharma.com

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.